Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

    Mark Vickery headshot

    Top Research Reports for Johnson & Johnson, Visa & Verizon

    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ).

      J&J's Esketamine Fails to Meet Endpoint in Phase III Study

      J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.

        AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

        AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

          J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

          Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

            Aduro's Cancer Arm & Strong Collaborations Boost Growth

            Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

              Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

              Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

                Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

                Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

                  Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

                  Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                    Kinjel Shah headshot

                    Is Artificial Intelligence the Next Big Thing in Biotech?

                    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

                      Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

                      Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

                        Pharma/Biotech Stocks to Watch This Prostate Cancer Month

                        Here we highlight a few companies that are focused on developing treatments for prostate cancer.

                          Shire's ADHD Portfolio Remains Strong Amid Competition

                          Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

                            Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod

                            Perrigo (PRGO) announces approval of over-the-counter equivalent of Imodium Multi-Symptom Relief tablet in the United States.

                              The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                              The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                                Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

                                Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

                                  Kinjel Shah headshot

                                  Lilly, Teva, Pfizer & Others Await FDA Decisions in September

                                  FDA grants approval to 34 new treatments this year so far.

                                    Indrajit Bandyopadhyay headshot

                                    Large Cap Pharma Stocks Staging a Comeback in Second Half

                                    Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.

                                      J&J Submits NDA to the FDA for Depression Drug in Adults

                                      Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.

                                        Geron Stock Up More Than 200% in 2018 So Far: Here's Why

                                        Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.

                                          Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

                                          Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

                                            AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

                                            AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

                                              Bayer's Blood Thinner Xarelto Fails in Line Extension Studies

                                              Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.

                                                AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma

                                                AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, BP, eBay and BCE

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, BP, eBay and BCE